Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2024-04-25 Board/Management Inform…
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo mit Veränderungen im Führungsteam
Board/Management Information Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and announces significant changes in the company's senior management (CEO appointment, Board President transition) and upcoming board nominations to be voted on at the General Meeting (Generalversammlung). This content directly relates to changes in the board of directors and senior management personnel. Therefore, the most appropriate classification is Board/Management Information (MANG). Although it mentions the Generalversammlung (AGM) and provides a link to the full invitation/proxy statement, the primary focus of this specific announcement is the management changes, not the AGM materials themselves or the voting results.
2024-04-25 German
Cosmo and Medtronic unveil the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
Regulatory Filings Classification · 95% confidence The document is a press release dated April 12, 2024, announcing advancements in AI for endoscopic care (ColonPRO software launch and collaboration with Medtronic/ModMed) presented at the Genius Summit 2024. It details product updates, strategic partnerships, and includes quotes from management. It is not a formal regulatory filing like a 10-K or IR. It is an announcement of business/product news. While it mentions upcoming events like the Annual Report and AGM, the core content is a business update. This type of announcement, detailing strategic developments and product news, most closely aligns with a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it contained summary financial figures, but since it focuses purely on product/partnership news, RNS is the most appropriate general category for non-standard announcements, or potentially a specialized Investor Presentation (IP) if it were structured as slides, but as a press release, RNS is the best fit among the options provided for general corporate news releases that aren't explicitly earnings or capital structure changes. Given the context of a major product/collaboration announcement, RNS (Regulatory Filings/General Announcement) is the most suitable fallback for significant, non-periodic corporate news.
2024-04-12 English
Cosmo und Medtronic stellen die Zukunft der KI im Endoskopie-Bereich vor: Genius Summit 2024 zeigt Innovationen und Kooperationen, welche die endoskopische Versorgung voranbringen
Regulatory Filings Classification · 100% confidence The document is a press release dated April 12, 2024, announcing advancements in AI for endoscopy (GI Genius system updates and a new strategic collaboration between Cosmo and Medtronic) presented at the Genius Summit 2024. It contains company updates, product news, executive quotes, and a financial calendar. This format is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses on operational and product news rather than strictly financial results (which are scheduled for April 30, 2024, according to the calendar), and it is not a transcript (CT), a formal report (10-K, IR), or a proxy statement (DEF 14A), the most appropriate classification is Earnings Release (ER) as it serves as an initial communication of significant business developments, even if not strictly quarterly figures. However, given the nature of the announcement (partnership, product update, event summary) and the presence of a 'Financial Calendar' which points to future formal reports, it functions primarily as a general corporate update. Since it is a press release announcing business developments and not a formal regulatory filing like a 10-K or a specific report like an AR, and it's not a transcript, the best fit among the specific options is ER, as these types of announcements often accompany or precede earnings periods. If 'RNS' (Regulatory Filings/General Announcement) were chosen, it would be a fallback, but ER captures the context of business performance updates better here.
2024-04-12 German
Cosmo reports excellent preliminary unaudited Full Year 2023 core financial results - Record guidance for 2024 - Doubles dividend to € 2.00 per share
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement' and provides 'preliminary unaudited Full Year 2023 core financial results' along with guidance for 2024. It contains detailed financial highlights, operational updates (GI Genius, Winlevi), pipeline progress, and concludes with an invitation to a live conference call to discuss these results. This structure—announcing preliminary results and providing context before the final audited report—is characteristic of an Earnings Release (ER). Although it mentions the preliminary unaudited Annual Report 2023 is available for download, the primary function of this document is the immediate release of key financial performance indicators and forward-looking guidance, which aligns best with the ER definition. It is not the full 10-K, nor is it just a notice of publication (RPA) since it contains substantial data. FY 2023
2024-03-20 English
Cosmo meldet hervorragende vorläufige ungeprüfte Kern-Finanzergebnisse für das Gesamtjahr 2023 - Rekord-Guidance für 2024 - Verdoppelung der Dividende auf EUR 2.00 pro Aktie
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and presents 'hervorragende vorläufige ungeprüfte Kern-Finanzergebnisse für das Gesamtjahr 2023' (excellent preliminary unaudited core financial results for the full year 2023). It includes detailed preliminary financial tables, management commentary, guidance for 2024, and an announcement regarding a proposed dividend increase. This structure strongly indicates an initial release of periodic financial results, which aligns with the definition of an Earnings Release (ER). Although it contains detailed financial data, it explicitly states the results are 'vorläufige ungeprüfte' (preliminary unaudited) and is structured as a press release announcing these results, rather than the comprehensive, audited Annual Report (10-K) or a formal Interim Report (IR). The document also mentions that the full report and presentation are available for download, suggesting this is the announcement itself. FY 2023
2024-03-20 German
Cosmo Pharmaceuticals announces approval of Winlevi® in Australia
Earnings Release Classification · 99% confidence The document is a press release dated March 19, 2024, announcing that Cosmo Pharmaceuticals' partner, Sun Pharma, received regulatory approval from the Australian TGA for the drug Winlevi®. This type of announcement, detailing a specific business development (product approval/partnership update) rather than comprehensive financial results (like 10-K or IR) or a formal regulatory filing, is best classified as a general corporate announcement. Since it is not a specific filing type like Director's Dealing, Capital Change, or Dividend Notice, and it is a formal announcement, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news releases that don't fit elsewhere. The document length (6971 chars) is substantial enough that it is not merely a 'Report Publication Announcement' (RPA) pointing to a larger document, but the content itself is the news release. FY 2023
2024-03-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.